Literature DB >> 21984836

Effects of repeated 3,4-methylenedioxymethamphetamine administration on neurotransmitter efflux and sensory-evoked discharge in the ventral posterior medial thalamus.

M A Starr1, M E Page, B D Waterhouse.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA) is known to enhance tactile sensory perception, an effect that contributes to its popularity as a recreational drug. The neurophysiological basis for the effects of MDMA on somatosensation are unknown. However, MDMA interactions with the serotonin transporter (SERT) and subsequent enhancement of serotonin neurotransmission are well known. The rat trigeminal somatosensory system receives serotonergic afferents from the dorsal raphe nucleus. Because these fibers express SERT, they should be vulnerable to MDMA-induced effects. We found that administration of a challenge injection of MDMA (3 mg/kg i.p.) after repeated MDMA treatment (3 mg/kg per day for 4 days) elicits both serotonin and norepinephrine efflux in the ventral posterior medial (VPM) thalamus of Long-Evans hooded rats, the main relay along the lemniscal portion of the rodent trigeminal somatosensory pathway. We evaluated the potential for repeated MDMA administration to modulate whisker-evoked discharge of individual neurons in this region. After surgically implanting stainless steel eight-wire multichannel electrode bundles, we recorded spike train activity of single cells while activating the whisker pathway using a piezoelectric mechanical stimulator. We found that repeated MDMA administration increased the spontaneous firing rate but reduced both the magnitude and duration of whisker-evoked discharge in individual VPM thalamic neurons. The time course of drug action on neuronal firing patterns was generally consistent with fluctuations in neurotransmitter efflux as shown from our microdialysis studies. On the basis of these results, we propose that single use and repeated administration of MDMA may "distort," rather than enhance, tactile experiences in humans, in part, by disrupting normal spike firing patterns through somatosensory thalamic relay circuits.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21984836      PMCID: PMC3251029          DOI: 10.1124/jpet.111.185728

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  29 in total

1.  MDMA elicits behavioral and neurochemical sensitization in rats.

Authors:  P W Kalivas; P Duffy; S R White
Journal:  Neuropsychopharmacology       Date:  1998-06       Impact factor: 7.853

2.  Acute administration of 3,4-methylenedioxymethamphetamine (MDMA) induces oxidative stress, lipoperoxidation and TNFα-mediated apoptosis in rat liver.

Authors:  D Cerretani; S Bello; S Cantatore; A I Fiaschi; G Montefrancesco; M Neri; C Pomara; I Riezzo; C Fiore; A Bonsignore; E Turillazzi; V Fineschi
Journal:  Pharmacol Res       Date:  2011-08-12       Impact factor: 7.658

3.  Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat.

Authors:  H M Marston; M E Reid; J A Lawrence; H J Olverman; S P Butcher
Journal:  Psychopharmacology (Berl)       Date:  1999-05       Impact factor: 4.530

4.  Mechanism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated mitochondrial dysfunction in rat liver.

Authors:  Kwan-Hoon Moon; Vijay V Upreti; Li-Rong Yu; Insong J Lee; Xiaoying Ye; Natalie D Eddington; Timothy D Veenstra; Byoung-Joon Song
Journal:  Proteomics       Date:  2008-09       Impact factor: 3.984

5.  Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses.

Authors:  Melanie Mueller; Frank T Peters; Hans H Maurer; Una D McCann; George A Ricaurte
Journal:  J Pharmacol Exp Ther       Date:  2008-06-30       Impact factor: 4.030

6.  Behavioral, thermal and neurochemical effects of acute and chronic 3,4-methylenedioxymethamphetamine ("Ecstasy") self-administration.

Authors:  Maria Elena Reveron; Esther Y Maier; Christine L Duvauchelle
Journal:  Behav Brain Res       Date:  2009-11-03       Impact factor: 3.332

7.  MDMA (3,4-methylenedioxymethamphetamine)-mediated distortion of somatosensory signal transmission and neurotransmitter efflux in the ventral posterior medial thalamus.

Authors:  M A Starr; M E Page; B D Waterhouse
Journal:  J Pharmacol Exp Ther       Date:  2008-07-07       Impact factor: 4.030

8.  Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat.

Authors:  Michael H Baumann; Dorota Zolkowska; Insook Kim; Karl B Scheidweiler; Richard B Rothman; Marilyn A Huestis
Journal:  Drug Metab Dispos       Date:  2009-08-13       Impact factor: 3.922

9.  Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges.

Authors:  M H Baumann; R D Clark; F H Franken; J J Rutter; R B Rothman
Journal:  Neuroscience       Date:  2008-01-12       Impact factor: 3.590

10.  In vivo pharmacology of MDMA and its enantiomers in rhesus monkeys.

Authors:  William E Fantegrossi
Journal:  Exp Clin Psychopharmacol       Date:  2008-02       Impact factor: 3.157

View more
  2 in total

1.  Mechanisms and environmental factors that underlying the intensification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced serotonin syndrome in rats.

Authors:  Rui Tao; Ibrahim M Shokry; John J Callanan; H Daniel Adams; Zhiyuan Ma
Journal:  Psychopharmacology (Berl)       Date:  2014-10-11       Impact factor: 4.530

2.  Characterization of electroencephalographic and biochemical responses at 5-HT promoting drug-induced onset of serotonin syndrome in rats.

Authors:  Zhiyuan Ma; Mary Rudacille; Howard M Prentice; Rui Tao
Journal:  J Neurochem       Date:  2013-01-28       Impact factor: 5.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.